ArticleAmerican journal of cancer research2022

De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.

Fu Ou-Yang et al.PubMed ↗Full text ↗

No numbers read from the abstract.